ARTICLE | Clinical News

Zerenex ferric citrate: Completed Phase III enrollment

November 8, 2010 8:00 AM UTC

Keryx completed enrollment of about 150 patients in an open-label, U.S. Phase III trial to evaluate once-daily 1, 6 or 8 g oral Zerenex for 28 days. The partners have an SPA from FDA for the trial. Ke...